Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Accounts Payables: 2009-2024

Historic Accounts Payables for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $2.1 million.

  • Ironwood Pharmaceuticals' Accounts Payables fell 50.15% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 50.15%. This contributed to the annual value of $2.1 million for FY2024, which is 72.84% down from last year.
  • According to the latest figures from FY2024, Ironwood Pharmaceuticals' Accounts Payables is $2.1 million, which was down 72.84% from $7.8 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Accounts Payables registered a high of $7.8 million during FY2023, and its lowest value of $483,000 during FY2022.
  • For the 3-year period, Ironwood Pharmaceuticals' Accounts Payables averaged around $3.5 million, with its median value being $2.1 million (2024).
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Accounts Payables plummeted by 83.38% in 2020 and then surged by 1,521.12% in 2023.
  • Yearly analysis of 5 years shows Ironwood Pharmaceuticals' Accounts Payables stood at $661,000 in 2020, then spiked by 41.45% to $935,000 in 2021, then slumped by 48.34% to $483,000 in 2022, then spiked by 1,521.12% to $7.8 million in 2023, then slumped by 72.84% to $2.1 million in 2024.